

REFERENCES

- Bergström JD, Westermarck B, H.N. (2000) Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. *Experimental Cell Research*. 259 (1), pp. 293–299. doi:10.1006/excr.2000.4967.
- Bounacer, a, Wicker, R., Caillou, B., Cailleux, a F., Sarasin, A., Schlumberger, M. and Suárez, H.G. (1997) High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. *Oncogene* [online]. 15 (11), pp. 1263–1273. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/12670889>doi:10.1038/sj.onc.1200206.
- Burgess, A.W., Cho, H.S., Eigenbrot, C., Ferguson, K.M., Garrett, T.P.J., Leahy, D.J., Lemmon, M.A., Sliwkowski, M.X., Ward, C.W. and Yokoyama, S. (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. *Molecular Cell*. 12 (3), pp. 541–552. doi:10.1016/S1097-2765(03)00350-2.
- Christopher, R., Rajivnath, V. and Shetty, K.T. (1997) *Arginase deficiency* [online].
- De Biase, D., Visani, M., Malapelle, U., Simonato, F., Cesari, V., Bellevicine, C., Pession, A., Troncone, G., Fassina, A. and Tallini, G. (2013) Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy). *PLoS ONE*. 8 (12), pp. 1–13. doi:10.1371/journal.pone.0083607.
- Giunti, S., Antonelli, A., Amorosi, A. and Santarpia, L. (2013) Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma. *International Journal of Endocrinology*. 2013 . doi:10.1155/2013/803171.
- Hartmann, J.T., Haap, M., Kopp, H.-G. and Lipp, H.-P. (2009) Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. *Current drug metabolism* [online]. 10 (5), pp. 470–481. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19689244>doi:10.2174/138920009788897975.
- Hirata, A., Hosoi, F., Miyagawa, M., Ueda, S.I., Naito, S., Fujii, T., Kuwano, M. and Ono, M. (2005) HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. *Cancer Research*. 65 (10), pp. 4253–4260. doi:10.1158/0008-5472.CAN-04-2748.

- Jin, S., Borkhuu, O., Bao, W. and Yang, Y.-T. (2016) Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications. *Journal of clinical medicine research* [online]. 8 (4), pp. 284–296. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4780491&tool=pmcentrez&rendertype=abstract>doi:10.14740/jocmr2480w.
- Jin, Y., Chen, M. and Yu, X. (2016) Differences among lesions with exon 19, exon 21 EGFR mutations and wild types in surgically resected non-small cell lung cancer. *Scientific reports* [online]. 6 (August), pp. 31636. Available from: <http://dx.doi.org/10.1038/srep31636>doi:10.1038/srep31636.
- Kilfoy, B.A., Devesa, S.S., Ward, M.H., Zhang, Y., Rosenberg, P.S., Holford, T.R. and Anderson, W.F. (2009) Gender is an age-specific effect modifier for papillary cancers of the thyroid gland. *Cancer Epidemiology Biomarkers and Prevention*. 18 (4), pp. 1092–1100. doi:10.1158/1055-9965.EPI-08-0976.
- Lemmon, M.A. and Schlessinger, J. (2010) Cell signaling by receptor tyrosine kinases. *Cell* [online]. 141 (7), pp. 1117–1134. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/11057895>doi:10.1016/j.cell.2010.06.011.
- Linder, L. and City, S.L. (2015) *HHS Public Access*. 27 (6), pp. 316–324. doi:10.1177/1043454210368532.Analysis.
- Lote, H., Bhosle, J., Brien, M.O. and Newbold, K. (2014) *Epidermal Growth Factor Mutation as a Diagnostic and Therapeutic Target in Metastatic Poorly Differentiated Thyroid Carcinoma : A Case Report and Review of the Literature*. pp. 393–400. doi:10.1159/000364856.
- Louise Davies, MD, MS; H. Gilbert Welch, MD, M. (2006) Increasing Incidence of Thyroid Cancer in the United States, 1973-2002. *JAMA Network* [online]. Available from: <http://jamanetwork.com/journals/jama/fullarticle/202835>doi:10.1001/jama.295.18.2164.
- Lovly, C., L. Horn, W. Pao. 2015. EGFR in Non-Small Cell Lung Cancer (NSCLC). *My Cancer Genome* <https://www.mycancergenome.org/content/disease/lung-cancer/egfr/> (Updated June 18)
- Lupi, C., Giannini, R., Ugolini, C., Proietti, A., Berti, P., Minuto, M., Materazzi, G., Elisei, R., Santoro, M., Miccoli, P. and Basolo, F. (2007) Extensive clinical experience: Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. *Journal of Clinical Endocrinology and Metabolism*. 92 (11), pp. 4085–4090. doi:10.1210/jc.2007-1179.

- Masago, K., Asato, R., Fujita, S., Hirano, S., Tamura, Y., Kanda, T., Mio, T., Katakami, N., Mishima, M. and Ito, J. (2009) Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma. *Int J Cancer* [online]. 124 (11), pp. 2744–2749. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/19253367>doi:10.1002/ijc.24250.
- Myers, M.B., Mckim, K.L. and Parsons, B.L. (2014) A subset of papillary thyroid carcinomas contain KRAS mutant subpopulations at levels above normal thyroid. *Molecular Carcinogenesis*. 53 (2), pp. 159–167. doi:10.1002/mc.21953.
- NCI's Division of Cancer Control and Population Sciences (no date) *No Title*. Available from: https://seer.cancer.gov/csr/1975_2013/browse_csr.php?sectionSEL=26&pageSEL=sect_26_table.05.html [Accessed 20 December 2016].
- Niitsu, H., Hinoi, T., Kawaguchi, Y., Sentani, K., Yuge, R., Kitadai, Y., Sotomaru, Y., Adachi, T., Saito, Y., Miguchi, M., Kochi, M., Sada, H., Shimomura, M., Oue, N., et al. (2016) KRAS mutation leads to decreased expression of regulator of calcineurin 2, resulting in tumor proliferation in colorectal cancer. *Oncogenesis* [online]. 5 (8), pp. e253. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27526107>doi:10.1038/oncsis.2016.47.
- Oncology, F.O.R. and Only, U.S.E. (no date) 250 Mg.
- Ono, M. and Kuwano, M. (2006) Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. *Clinical Cancer Research*. 12 (24), pp. 7242–7251. doi:10.1158/1078-0432.CCR-06-0646.
- Pellegriti, G., Frasca, F., Regalbuto, C., Squatrito, S. and Vigneri, R. (2013) Worldwide increasing incidence of thyroid cancer: Update on epidemiology and risk factors. *Journal of Cancer Epidemiology*. 2013 . doi:10.1155/2013/965212.
- Pisani, C.P., Buzzoni, C., Crocetti, E., Maso, L.D., Rondelli, R., Alessi, D., Aricò, M., Bidoli, E., Ferrari, A., Fusco, M., Gatta, G., Guzzinati, S., Jankovic, M., Locatelli, F., et al. (2012) *Cancer in children and adolescents*. pp. 144–149.
- Rahbari, R., Zhang, L. and Kebebew, E. (2010) Thyroid cancer gender disparity. *Future oncology (London, England)* [online]. 6 (11), pp. 1771–1779. Available from: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3077966&tool=pmcentrez&rendertype=abstract>doi:10.2217/fon.10.127.

- Rajoria, S., Suriano, R., Shanmugam, A., Wilson, Y.L., Schantz, S.P., Geliebter, J. and Tiwari, R.K. (2010) *Metastatic Phenotype Is Regulated by Estrogen in Thyroid Cells*. 20 (1), .
- Schiff, B.A., Mcmurphy, A.B., Jasser, S.A., Younes, M.N., Doan, D., Yigitbasi, O.G., Kim, S., Zhou, G., Mandal, M., Bekele, B.N., Holsinger, F.C., Sherman, S.I., Yeung, S., El-naggar, A.K., et al. (2004) *Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer , and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer*. 10 pp. 8594–8602.
- Spatz, M.A. (2004) Genetics Home Reference. *Journal of the Medical Library Association* [online]. 92 (2), pp. 282–283. Available from: <https://ghr.nlm.nih.gov/condition/meniere-disease#inheritance>doi:10.1300/J381v09n04_07.
- The uniprot consortium (2013) *EGFR epidermal growth factor receptor [Homo sapiens]*. Available from: <http://www.uniprot.org/uniprot/P00533> [Accessed 10 October 2016].
- Weir, H.K., Thompson, T.D., Soman, A., Müller, B. and Leadbetter, S. (2015) The past, present, and future of cancer incidence in the United States: 1975 through 2020. *Cancer* [online]. 121 (11), pp. 1827–1837. Available from: <http://doi.wiley.com/10.1002/cncr.29258>doi:10.1002/cncr.29258.